We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Solventum Corporation (SOLV) This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Solventum (SOLV - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Solventum is one of 946 individual stocks in the Medical sector. Collectively, these companies sit at #6 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Solventum is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for SOLV's full-year earnings has moved 1.6% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, SOLV has moved about 21.2% on a year-to-date basis. Meanwhile, stocks in the Medical group have gained about 7.9% on average. This means that Solventum is performing better than its sector in terms of year-to-date returns.
Cronos Group (CRON - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 31.7%.
The consensus estimate for Cronos Group's current year EPS has increased 87.5% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
Breaking things down more, Solventum is a member of the Medical Services industry, which includes 62 individual companies and currently sits at #160 in the Zacks Industry Rank. Stocks in this group have gained about 7.6% so far this year, so SOLV is performing better this group in terms of year-to-date returns.
On the other hand, Cronos Group belongs to the Medical - Drugs industry. This 146-stock industry is currently ranked #82. The industry has moved +8.4% year to date.
Investors interested in the Medical sector may want to keep a close eye on Solventum and Cronos Group as they attempt to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging Solventum Corporation (SOLV) This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Solventum (SOLV - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Solventum is one of 946 individual stocks in the Medical sector. Collectively, these companies sit at #6 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Solventum is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for SOLV's full-year earnings has moved 1.6% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, SOLV has moved about 21.2% on a year-to-date basis. Meanwhile, stocks in the Medical group have gained about 7.9% on average. This means that Solventum is performing better than its sector in terms of year-to-date returns.
Cronos Group (CRON - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 31.7%.
The consensus estimate for Cronos Group's current year EPS has increased 87.5% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
Breaking things down more, Solventum is a member of the Medical Services industry, which includes 62 individual companies and currently sits at #160 in the Zacks Industry Rank. Stocks in this group have gained about 7.6% so far this year, so SOLV is performing better this group in terms of year-to-date returns.
On the other hand, Cronos Group belongs to the Medical - Drugs industry. This 146-stock industry is currently ranked #82. The industry has moved +8.4% year to date.
Investors interested in the Medical sector may want to keep a close eye on Solventum and Cronos Group as they attempt to continue their solid performance.